Roche "outperform"

12/20/05 - Credit Suisse First Boston

LONDON, December 20 (newratings.com) - Analysts at Credit Suisse First Boston maintain their "outperform" rating on Roche GS (ROG). The target price is set to CHF208.

In a research note published this morning, the analysts mention that the company’s sales and profitability are expected to improve significantly going forward. According to the analysts, the consensus sales projections for Avastin for 2008 possibly include the impact of pricing reductions and no further approval of indications.